Adverts

Open Access Articles- Top Results for Ketotifen

Ketotifen

</th></tr></th></tr>
Ketotifen
150px
Systematic (IUPAC) name
4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
Clinical data
Trade names Zaditor[1]
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a604033
  • US: C (Risk not ruled out)
  • US: Oral - Prescription; Eye Drops - OTC
Oral, Eye Drops
Pharmacokinetic data
Bioavailability 60%
Protein binding 75%
Metabolism Hepatic
Half-life 12 Hours
Identifiers
34580-14-8 7pxY
R06AX17 S01GX08
PubChem CID 3827
DrugBank DB00920 7pxY
ChemSpider 3695 7pxY
UNII HBD503WORO 7pxY
KEGG D01332 7pxY
ChEMBL CHEMBL534 7pxY
Chemical data
Formula C19H19NOS
309.426 g/mol
 14pxY (what is this?)  (verify)

Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis,[2] or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.

Uses

Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three.[2] The mean elimination half life is 12 hours.[3] Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.

The drug may also help relieve the symptoms of irritable bowel syndrome.[4]

Side effects

Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.

Brands

Ketotifen is marketed under many brand names worldwide.[5]

See also

References

  1. ^ http://www.webmd.com/drugs/2/drug-17484/zaditor-opht/details
  2. ^ a b Zaditor prescribing information Novartis
  3. ^ Grahnén A; Lönnebo A; Beck O; Eckernäs SA; Dahlström B; Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharm Drug Dispos 13 (4): 255–262. PMID 1600111. doi:10.1002/bdd.2510130404. 
  4. ^ Klooker, TK; Braak, B; Koopman, KE; Welting, O; Wouters, MM; Van Der Heide, S; Schemann, M; Bischoff, SC et al. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut 59 (9): 1213–21. PMID 20650926. doi:10.1136/gut.2010.213108. 
  5. ^ drugs.com International availability of ketofin Page accessed April 21, 2015

External links